A Study of Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy

Epilepsy Clinical Trial

Official title:

A Phase 2, Double-blind, Randomized, Placebo-controlled Pharmacokinetic Trial in 2 Parallel Groups to Investigate Possible Drug-drug Interactions Between Stiripentol or Valproate and GWP42003-P in Patients With Epilepsy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02607891
• Other study ID #: GWEP1447 Blinded Phase
• Secondary ID: 2015-002939-18
• Status: Completed
• Phase: Phase 2
• Start date: November 9, 2016
• Est. completion date: October 2, 2018

Study information

• Verified date: December 2022
• Source: Jazz Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This trial consists of 2 parts: a double-blinded phase and an open-label extension phase. The blinded phase only will be described in this record. Participants will be randomized in a 4:1 ratio to receive GWP42003-P or matching placebo. The hypothesis is that levels of stiripentol (STP) or valproate (VPA) may be altered (increased or decreased) as a result of using GWP42003-P.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 35
• Est. completion date: October 2, 2018
• Est. primary completion date: September 11, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years to 55 Years

Eligibility

Note: Participants who enroll in Sweden must be aged 18-55 years.

Key Inclusion Criteria:

• Participant must be taking STP (for the STP arm) or VPA (for the VPA arm) and no more than 2 other antiepileptic drugs (AEDs) during the blinded period of the trial.

• In the VPA arm only, the participant must not be receiving STP (VPA allowed in STP arm).

• AED doses, including STP or VPA, must be stable for 4 weeks prior to screening and regimen must remain stable throughout the duration of the blinded period of the trial.

• Participant must have a documented magnetic resonance imaging/computerized tomography of the brain that ruled out a progressive neurologic condition.

• Participant must have experienced at least 1 countable uncontrolled seizure of any type (i.e., tonic-clonic, tonic, clonic, atonic, partial onset or focal: focal seizures with retained consciousness and a motor component, focal seizures with impaired consciousness, focal seizures evolving to bilateral secondary generalization) within 2 months prior to randomization.

• Intervention with vagus nerve stimulation and/or ketogenic diet must be stable for 4 weeks prior to baseline and the participant must be willing to maintain a stable regimen during the blinded period of the trial.

• Participant must abstain from alcohol during the blinded period of the trial.

Key Exclusion Criteria:

• Participant has clinically significant unstable medical conditions other than epilepsy.

• Participant has a history of symptoms related to a drop in blood pressure due to postural changes (e.g., dizziness, light-headedness, blurred vision, palpitations, weakness, syncope).

• Participant has a QT interval, corrected for heart rate with Bazett's formula (QTcB), greater than:

• 450 msec for males.

• 470 msec for females.

• 480 msec if right bundle branch block is present.

• Participant has any history of suicidal behavior or any suicidal ideation of type 4 or 5 on the C-SSRS in the last month or at screening.

• Participant has had clinically relevant symptoms or a clinically significant illness in the 4 weeks prior to screening or enrollment, other than epilepsy.

• Participant is currently using felbamate and has been taking it for less than 12 months prior to screening.

• Participant has consumed alcohol during the 7 days prior to enrollment and is unwilling to abstain during the blinded phase of the trail.

• Participant is currently using or has in the past used recreational or medicinal cannabis, or synthetic cannabinoid-based medications (including Sativex®) within the 3 months prior to trial entry.

• Participant has any known or suspected history of any drug abuse or addiction.

• Participant is unwilling to abstain from recreational or medicinal cannabis, or synthetic cannabinoid based medications (including Sativex) for the duration for the study.

• Participant has consumed grapefruit or grapefruit juice 7 days prior to enrollment and is unwilling to abstain from drinking grapefruit juice within 7 days of pharmacokinetic visits.

• Participant has any known or suspected hypersensitivity to cannabinoids or any of the excipients of the Investigational Medicinal Product (IMP), e.g., sesame oil.

• Participant has received an IMP within the 12 weeks prior to the screening visit.

• Participant has significantly impaired hepatic function at the screening or randomization visit, defined as any of the following:

• Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 5 × upper limit of normal (ULN).

• ALT or AST > 3 × ULN and total bilirubin (TBL) > 2 × ULN or international normalized ratio (INR) > 1.5.

• ALT or AST > 3 × ULN with the presence of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (> 5%).

Related Conditions & MeSH terms

• Epilepsy

Intervention

Drug:
• GWP42003-P
Clear, colorless to yellow solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
• Placebo
Clear, colorless to yellow solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.

Locations

Country	Name	City	State
Netherlands	SEIN - Epilepsy Institute in the Netherlands Foundation	Zwolle
Spain	Hospital Universitari Vall d'Hebron	Barcelona
Spain	Hospital Ruber Internacional	Madrid
Spain	Hospital Universitario Virgen del Rocio	Sevilla
Sweden	Sahlgrenska University Hospital	Göteborg

Sponsors (1)

Lead Sponsor	Collaborator
Jazz Pharmaceuticals

Countries where clinical trial is conducted

Netherlands,  Spain,  Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum plasma concentration (Cmax) of STP, VPA, cannabidiol (CBD).	The Cmax of STP, VPA and CBD is presented.	0, 0.25, 0.5, 1, 1.5, 2, 4, 6, and 12 hours post-dose.
Primary	Time to the maximum plasma concentration (Tmax) of STP, VPA and CBD.	The Tmax of STP, VPA and CBD is presented.	0, 0.25, 0.5, 1, 1.5, 2, 4, 6, and 12 hours post-dose.
Primary	Area under the curve (AUC) from zero to final time of positive detection (0-t) of STP, VPA and CBD.	The AUC(0-t) of STP, VPA and CBD is presented.	0, 0.25, 0.5, 1, 1.5, 2, 4, 6, and 12 hours post-dose.
Primary	Area under the plasma concentration time curve over a dosing interval, where tau is the dosing interval [AUCtau].	The AUC(tau) of STP, VPA, and CBD is presented.	0, 0.25, 0.5, 1, 1.5, 2, 4, 6, and 12 hours post-dose.
Secondary	Number of participants who experienced an adverse event.	The number of participants who experienced an adverse event during the trial is presented.	Up to 11 weeks.
Secondary	Number of participants with a clinically significant change in 12-lead electrocardiogram (ECG).	The number of participants with a clinically significant change in ECG is presented.	Up to 7 weeks.
Secondary	Number of participants with a clinically significant change in serum biochemistry.	The number of participants with a clinically significant change in serum biochemistry is presented.	Up to 7 weeks.
Secondary	Number of participants with a clinically significant change in hematology.	The number of participants with a clinically significant change in hematology is presented.	Up to 7 weeks.
Secondary	Number of participants with a clinically significant change in urinalysis.	The number of participants with a clinically significant change in urinalysis is presented.	Up to 7 weeks.
Secondary	Number of participants with a clinically significant change in vital signs.	The number of participants with a clinically significant change in vital signs (systolic blood pressure, diastolic blood pressure, pulse rate) is presented.	Up to 7 weeks.
Secondary	Number of participants with a clinically significant change in physical examination.	The number of participants with a clinically significant change in physical examination is presented.	Up to 7 weeks.
Secondary	Number of participants with a treatment-emergent suicidality flag.	Suicidality was assessed using the Columbia-Suicide Severity Rating Scale (C-SSRS). The number of participants with a treatment-emergent flag is presented.	Up to 7 weeks.
Secondary	Seizure frequency by subtype.	The frequency of each subtype of seizure at baseline and end of treatment is presented.	Up to 6 weeks.
Secondary	Number of participants with a treatment-emergent finding indicative of drug abuse liability.	Abuse liability was assessed through monitoring of triggering adverse events of interest and study medication accountability discrepancies. Any findings were assigned to an appropriate classification by the investigator. The number of participants with a treatment-emergent finding indicative of drug abuse liability is presented.	Up to 7 weeks.
Secondary	Cmax of 4-ene-VPA, clobazam (CLB), N-desmethylclobazam (N-CLB), levetiracetam (LEV), and topiramate (TOP).	The Cmax of 4-ene-VPA, CLB, N-CLB, LEV, and TOP is presented.	0, 0.25, 0.5, 1, 1.5, 2, 4, 6, and 12 hours post-dose.
Secondary	Tmax of 4-ene-VPA, CLB, N-CLB, LEV, and TOP.	The Tmax of 4-ene-VPA, CLB, N-CLB, LEV, and TOP is presented.	0, 0.25, 0.5, 1, 1.5, 2, 4, 6, and 12 hours post-dose.
Secondary	AUC(0-t) of 4-ene-VPA, CLB, N-CLB, LEV, and TOP.	The AUC(0-t) of 4-ene-VPA, CLB, N-CLB, LEV, and TOP is presented.	0, 0.25, 0.5, 1, 1.5, 2, 4, 6, and 12 hours post-dose.
Secondary	AUC(tau) of 4-ene-VPA, CLB, N-CLB, LEV, and TOP.	The AUC(tau) of 4-ene-VPA, CLB, N-CLB, LEV, and TOP is presented.	0, 0.25, 0.5, 1, 1.5, 2, 4, 6, and 12 hours post-dose.